0001209191-22-041342.txt : 20220706
0001209191-22-041342.hdr.sgml : 20220706
20220706182307
ACCESSION NUMBER: 0001209191-22-041342
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220705
FILED AS OF DATE: 20220706
DATE AS OF CHANGE: 20220706
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scalzo Richard William
CENTRAL INDEX KEY: 0001789545
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 221070090
MAIL ADDRESS:
STREET 1: 25 ALBERTA LANE
CITY: HOLLISTON
STATE: MA
ZIP: 01746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-05
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001789545
Scalzo Richard William
C/O DYNE THERAPEUTICS, INC.
1560 TRAPELO ROAD
WALTHAM
MA
02451
0
1
0
0
See Remarks
Stock Option (right to buy)
5.54
2022-07-05
4
A
0
17333
0.00
A
2030-07-30
Common Stock
17333
17333
D
The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
Vice President of Accounting and Administration and Treasurer
/s/ Richard Scalzo
2022-07-06